John Glasspool
Biopharmaceutical Leader
Boston, Massachusetts
Overview
Work Experience
Chief Executive Officer
2024 - Current
Member of the Board Emerging Companies Section Governing Board
2022
Venture Partner
2018
Agent Capital is a healthcare venture capital firm focused on investing in novel, differentiated therapeutics and treatments that address unmet patient needs.
A biotech venture capital firm.
Board Member
2019
Relmada (Nasdaq: $RLMD) is a clinical-stage company developing novel therapies for the treatment of CNS diseases.
Relmada Therapeutics is a biotech company addressing diseases of the central nervous system, with a focus on major depressive disorder.
Raised $306,131,110.00 from BioAdvance.
Senior Advisor
2016
Advisor/Contributor on key initiatives, including financing/reimbursement models, policy recommendations for durable therapies, and Efficacy to Effectiveness (E2E) strategies.
CEO and President
2019 - 2024
Anthos Therapeutics is a clinical-stage biopharmaceutical company developing innovative therapies for high-risk cardiovascular patients. The company’s lead program is abelacimab (MAA868), an antibody exhibiting dual inhibition of coagulation Factor XI and its activated form XIa. Early clinical trials indicate abelacimab has the potential to attenuate pathological thrombosis with minimal impact on hemostasis, thereby preventing or treating a variety of thrombotic disorders with lowered bleeding risk. Abelacimab’s anticipated monthly dosing combined with the potential for greater effectiveness and lowered bleeding profile are expected to provide major advantages over existing standards of care and allow greater numbers of people to be treated.
Anthos Therapeutics is a biopharmaceutical company that specializes in the treatment of cardiovascular and metabolic diseases.
Raised $250,000,000.00 from Blackstone Life Sciences and Novartis.
Board Member
2017 - 2023
DalCor is pioneering precision medicine for cardiovascular disease. The company is developing dalcetrapib, a unique cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile to maximize clinical benefit.
Consultant
2017 - 2018
Consulting to Roivant on commercial go-to-market activities, including operating, launch, and access plans.
EVP, Head of Corporate Strategy and Customer Operations
2015 - 2017
Member of Executive Team that led Baxalta through spin-off from Baxter Healthcare and subsequent merger agreement with Shire to form a Top 20 biopharma company. Championed external product development model and led Baxalta Ventures and Vitesse Biologics, along with more traditional business development and licensing and M&A, to create a conduit between innovation and commercialization.
Baxalta Incorporated (NYSE: BXLT) is a $6 billion global biopharmaceutical leader developing.
VP, Head of Emerging Therapies and Market Development, Bioscience
2012 - 2015
Built oncology franchise from the ground up with three in-licenses agreements and development of an internal commercial team. Architect of commercial infrastructure for $12 billion business built around the changing needs of multiple stakeholders – patients, physicians, providers, payers, and policymakers (P5) – establishing a comprehensive approach to the successful launch of new drugs.